Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 20Neoplasm Metastasis 4Skin Neoplasms 2Neoplasms 2Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Breast Neoplasms 1Brain Neoplasms 1Blast Crisis 1Anemia 1

Interventions

Vemurafenib 1PX-866 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced BRAF-mutant Cancers × Vemurafenib × Clear all
NCT01616199 2018-05-16

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Seagen Inc.

Phase 1/2 Terminated
24 enrolled

Advanced BRAF-mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡